Tofacitinib and TNF inhibitors demonstrated similar efficacy for managing RA at 12 months, with minor differences noted across tofacitinib treatment lines.

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.

Four studies looked at tofacitinib (Xeljanz) and one looked at filgotinib. Among 933 total patients, 44.7% received a JAK inhibitor, and 55.3% received vedolizumab. JAK Inhibitors Best Ustekinumab ...

"Giant cell arteritis is an inflammatory disease that, if left untreated, can lead to severe outcomes like blindness, stroke or aortic aneurysm,"2 said Prof. Dr. med. Wolfgang Schmidt, M.D., MACR, ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

Explore the efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease, highlighting potential risks like deep vein thrombosis.

The following is a summary of “Efficacy and safety of small molecule drugs in the treatment of pityriasis rubra pilaris—A systematic review,” published in the February 2025 issue of Frontiers in ...

including first-in-class JAK inhibitor Xeljanz (tofacitinib) for rheumatoid arthritis & ulcerative colitis, first-in-class Janus kinase 1 (JAK1) inhibitor Cibinqo (abrocitinib) for atopic ...

Spring House, Pennsylvania Monday, February 24, 2025, 09:00 Hrs [IST] ...